Innovations in Hypertension Management: A Contemporary Review 

Dr Neeraj Manikath , claude.ai

Abstract

Hypertension remains the leading modifiable risk factor for cardiovascular morbidity and mortality worldwide, affecting over 1.3 billion individuals globally. Despite decades of therapeutic advances, blood pressure control rates remain suboptimal, with only approximately 50% of treated patients achieving target goals. This review examines recent innovations in hypertension management, including novel pharmacotherapeutic approaches, device-based interventions, precision medicine strategies, and emerging diagnostic paradigms. We highlight practical pearls for the practicing internist and discuss how these advances may reshape hypertension care in the coming decade.

Introduction

The landscape of hypertension management has undergone significant evolution since the publication of landmark trials such as SPRINT (Systolic Blood Pressure Intervention Trial) and the subsequent revision of major guideline recommendations. Contemporary hypertension care now extends beyond traditional pharmacotherapy to encompass technological innovations, genetic profiling, and interventional approaches. Understanding these developments is essential for the modern internist to optimize patient outcomes and address the persistent challenge of treatment-resistant hypertension.

Novel Pharmacotherapeutic Approaches

Aldosterone Synthase Inhibitors

The recognition that mineralocorticoid receptor activation contributes significantly to hypertension and cardiovascular remodeling has spurred development of more selective agents targeting this pathway. Unlike traditional mineralocorticoid receptor antagonists (spironolactone, eplerenone), which block the receptor itself, aldosterone synthase inhibitors selectively inhibit the enzyme CYP11B2, thereby reducing aldosterone synthesis without affecting cortisol production.

Clinical Pearl: Aldosterone synthase inhibitors may offer improved tolerability compared to spironolactone, with lower rates of hyperkalemia and gynecomastia, though long-term cardiovascular outcome data are still pending.

Baxdrostat, a novel aldosterone synthase inhibitor, demonstrated promising results in the phase 2 BrigHTN trial, showing dose-dependent blood pressure reductions of up to 20/9 mmHg in treatment-resistant hypertension without significant hyperkalemia. These agents represent a paradigm shift in targeting the renin-angiotensin-aldosterone system (RAAS) with potentially superior safety profiles.

Dual Endothelin Receptor Antagonists

Aprocitentan, a dual endothelin A and B receptor antagonist, has emerged as a novel therapeutic option for resistant hypertension. The PRECISION study published in 2021 demonstrated that aprocitentan significantly reduced blood pressure in patients with resistant hypertension already receiving three or more antihypertensive agents, including a diuretic. The medication achieved FDA approval in 2024, marking the first new mechanistic class for resistant hypertension in over a decade.

Practice Hack: When considering aprocitentan, obtain baseline hemoglobin levels and monitor monthly for the first three months, as fluid retention and anemia are recognized adverse effects. Ensure patients are euvolemic before initiation.

Angiotensin Receptor-Neprilysin Inhibitors (ARNIs)

While sacubitril/valsartan gained initial prominence in heart failure management through the PARADIGM-HF trial, its role in hypertension is increasingly recognized. The PARAMETER trial demonstrated superior blood pressure reduction with sacubitril/valsartan compared to olmesartan in elderly patients with systolic hypertension and arterial stiffness. The dual mechanism—RAAS inhibition combined with neprilysin inhibition leading to increased natriuretic peptide levels—provides enhanced blood pressure lowering and potential vascular protective effects.

Clinical Oyster: Consider ARNIs particularly in hypertensive patients with elevated arterial stiffness (assessed by pulse wave velocity) or those with early diastolic dysfunction, as these agents may provide benefits beyond blood pressure reduction alone.

Precision Medicine and Pharmacogenomics

The recognition that hypertension represents a heterogeneous syndrome rather than a single disease has catalyzed interest in precision approaches. Pharmacogenomic testing can now identify genetic variants affecting drug metabolism and response, though clinical implementation remains limited.

Genotype-Guided Therapy

Polymorphisms in genes encoding drug-metabolizing enzymes (CYP2D6, CYP2C9) and drug targets (ADRB1, ACE) influence antihypertensive efficacy and adverse effect profiles. For instance, ADRB1 Arg389Gly polymorphism affects beta-blocker response, while CYP2C9 variants influence losartan metabolism.

Practice Hack: While routine pharmacogenomic testing isn't yet standard, consider it in patients with unexplained treatment resistance or unusual adverse effect patterns. Several commercial platforms now offer hypertension-specific pharmacogenetic panels.

Phenotype-Directed Treatment

Emerging evidence supports tailoring therapy based on identifiable patient phenotypes. The concept of "endotyping" classifies patients by underlying pathophysiological mechanisms:

• High-renin hypertension: More responsive to RAAS inhibitors
• Low-renin, volume-dependent hypertension: Better response to diuretics and calcium channel blockers
• Sympathetic-driven hypertension: May benefit from centrally-acting agents or device-based therapies

Plasma renin activity or direct renin concentration measurement, though not universally available, can guide initial drug selection in challenging cases.

Device-Based Interventions

Renal Denervation

After initial disappointment with the SYMPLICITY HTN-3 trial, renal denervation has experienced resurgence following refined techniques and improved patient selection. The SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED trials demonstrated significant blood pressure reductions with second-generation radiofrequency catheters. More recently, the RADIANCE-HTN SOLO trial showed ultrasound-based renal denervation effectively reduced blood pressure in patients discontinuing medications.

In 2023, the FDA approved the first renal denervation system, marking a significant milestone for device-based hypertension therapy. Current evidence suggests this approach is most beneficial for patients with moderate resistant hypertension who maintain medication adherence.

Clinical Pearl: Renal denervation should be considered for carefully selected patients with resistant hypertension after excluding secondary causes and confirming adherence. The procedure is contraindicated in patients with significant renal artery stenosis or severe chronic kidney disease (eGFR <30 mL/min/1.73m²).

Baroreflex Activation Therapy

Baroreflex activation therapy (BAT) involves implanting a device that electrically stimulates carotid baroreceptors, mimicking physiological blood pressure regulation. While earlier systems showed efficacy in resistant hypertension, newer second-generation devices offer improved tolerability and efficacy. The BeAT-HF trial demonstrated benefits in heart failure patients with hypertension, suggesting dual cardiovascular benefits.

Practice Hack: BAT may be particularly useful in patients with both resistant hypertension and heart failure with reduced ejection fraction, addressing both conditions simultaneously.

Central Iliac Arteriovenous Anastomosis

The ROX Coupler system creates a controlled arteriovenous fistula in the iliac vessels, leading to blood pressure reduction through decreased systemic vascular resistance. The ROX CONTROL HTN trial showed sustained blood pressure reductions at six months. While still investigational in many regions, this approach represents an innovative mechanical intervention for resistant hypertension.

Advanced Diagnostic Approaches

Artificial Intelligence and Machine Learning

Machine learning algorithms are increasingly applied to hypertension management, from risk prediction to treatment optimization. AI-powered systems can analyze multiple variables—demographic data, laboratory values, genetic information, and treatment history—to predict individual patient responses to specific medications.

Clinical Oyster: Several AI-based clinical decision support tools are now available to help predict which antihypertensive class will be most effective for individual patients, though prospective validation in diverse populations remains limited.

Wearable Technology and Remote Monitoring

The proliferation of validated home blood pressure monitoring devices and wearable technology has transformed hypertension care. Ambulatory blood pressure monitoring (ABPM) remains the gold standard for diagnosis, but newer wearables offering continuous or near-continuous monitoring may provide unprecedented insights into blood pressure patterns.

Practice Hack: When interpreting home blood pressure readings, ensure patients use validated devices (check the STRIDE-BP registry) and follow proper technique: seated position, back supported, feet flat on floor, arm at heart level, after five minutes of rest.

The integration of remote monitoring with telehealth platforms enables more frequent patient contact and timely medication adjustments, potentially improving control rates. Studies suggest remote monitoring combined with pharmacist-led interventions can achieve blood pressure control rates exceeding 70%.

Secondary Hypertension: Enhanced Detection Strategies

Approximately 10-15% of hypertension cases have identifiable secondary causes, yet these are frequently underdiagnosed. Recent advances facilitate detection:

Primary Aldosteronism

Previously considered rare, primary aldosteronism may affect 10-20% of patients with resistant hypertension. The aldosterone-to-renin ratio (ARR) serves as the primary screening test, but interpretation requires attention to medication effects. Many antihypertensives interfere with the RAAS, potentially causing false-negative results.

Practice Hack: For ARR screening, continue calcium channel blockers and alpha-blockers (minimal RAAS interference), but discontinue spironolactone for six weeks, and ACE inhibitors, ARBs, and beta-blockers for two weeks when feasible. Ensure adequate potassium repletion before testing, as hypokalemia suppresses aldosterone secretion.

Renal Artery Stenosis

While the CORAL trial dampened enthusiasm for renal artery stenting in atherosclerotic disease, identifying hemodynamically significant stenosis remains important for prognosis and select cases where revascularization may benefit. Doppler ultrasound serves as an initial screening tool, though CT or MR angiography provide superior anatomic detail.

Lifestyle Interventions: Evidence-Based Approaches

Despite pharmacological innovations, lifestyle modification remains foundational. Recent evidence has refined our understanding of specific interventions:

Dietary Approaches

The DASH diet continues to demonstrate robust blood pressure-lowering effects (approximately 11/6 mmHg reduction in hypertensive individuals). More recently, potassium supplementation has gained attention following the SSaSS trial, which showed potassium-enriched salt substitutes reduced cardiovascular events by 14% compared to regular salt.

Clinical Pearl: Recommend potassium-enriched salt substitutes cautiously in patients with chronic kidney disease (eGFR <30) or those taking potassium-sparing diuretics due to hyperkalemia risk.

Exercise Prescription

Both aerobic and resistance training reduce blood pressure, with optimal benefits from 150 minutes weekly of moderate-intensity activity. Isometric resistance training (sustained muscle contraction without movement, such as handgrip exercises) shows particular promise, with meta-analyses demonstrating reductions of 5-7 mmHg systolic pressure.

Treatment Strategies for Special Populations

Older Adults

The STEP trial from China confirmed that intensive blood pressure control (target <130 mmHg) in adults aged 60-80 years reduced cardiovascular events without increasing adverse effects. However, individualization remains crucial, considering frailty, comorbidities, and medication burden.

Practice Hack: In older adults with orthostatic hypotension, measure blood pressure in both seated and standing positions. If significant orthostasis exists (>20 mmHg systolic drop), optimize timing of antihypertensive administration (avoid bedtime dosing) and address reversible causes before intensifying treatment.

Chronic Kidney Disease

The optimal blood pressure target in CKD remains debated. While SPRINT included CKD patients and suggested benefits from intensive control, the KDIGO 2021 guidelines recommend tailored approaches. In patients with albuminuria >300 mg/day, lower targets (<120 mmHg systolic) may provide renoprotective benefits, whereas higher targets may be appropriate in elderly CKD patients without albuminuria.

Resistant Hypertension

Defined as blood pressure remaining above goal despite three maximally-tolerated antihypertensive agents (including a diuretic), resistant hypertension affects 10-15% of treated patients. A systematic approach includes:

1. Confirm true resistance: Verify with ABPM (exclude white-coat effect)
2. Assess adherence: Consider medication possession ratio, pill counts, or direct observation
3. Screen for secondary causes: Particularly primary aldosteronism and obstructive sleep apnea
4. Optimize diuretic therapy: Many patients benefit from switching from thiazides to chlorthalidone or adding spironolactone (25-50 mg daily)
5. Consider device-based therapies: After exhausting pharmacological options

Clinical Oyster: Obstructive sleep apnea affects up to 70% of patients with resistant hypertension. Screening with questionnaires (STOP-BANG) and treating with continuous positive airway pressure can significantly improve blood pressure control.

Implementation Strategies

Polypill Approach

Single-pill combinations containing multiple antihypertensive agents improve adherence and achieve superior blood pressure control compared to free-drug combinations. The SECURE trial demonstrated that a polypill containing aspirin, ramipril, and atorvastatin reduced cardiovascular events in secondary prevention. Similar polypills for primary hypertension management show promise.

Practice Hack: When initiating combination therapy, start with single-pill combinations when possible. This strategy enhances adherence and simplifies titration.

Team-Based Care Models

Collaborative care involving pharmacists, nurses, and community health workers improves blood pressure control rates. Pharmacist-led medication management programs, supported by collaborative practice agreements, have consistently demonstrated superior outcomes compared to usual physician-only care.

Future Directions

Several emerging areas warrant attention:

• RNA-based therapeutics: Small interfering RNAs targeting angiotensinogen or other hypertension-related genes are in early development
• Gut microbiome modulation: Emerging evidence links gut dysbiosis with hypertension, suggesting potential probiotic interventions
• Sodium-glucose cotransporter-2 (SGLT2) inhibitors: While primarily diabetes and heart failure medications, these agents modestly reduce blood pressure and may have specific roles in hypertensive patients with these comorbidities

Conclusion

Hypertension management has entered an exciting era characterized by novel therapeutic mechanisms, precision medicine approaches, and technological innovations. While traditional pharmacotherapy remains foundational, the modern internist must integrate newer modalities including device-based interventions, AI-assisted decision support, and personalized treatment strategies. Success requires moving beyond simple blood pressure reduction to comprehensive cardiovascular risk reduction, addressing adherence barriers, and individualizing therapy based on patient phenotypes and preferences. As these innovations become increasingly accessible, internists are well-positioned to leverage them for improved patient outcomes in this persistent global health challenge.

Key Takeaways for Practice

1. Consider aldosterone synthase inhibitors or aprocitentan for resistant hypertension when traditional agents prove insufficient
2. Implement home blood pressure monitoring with validated devices for all hypertensive patients
3. Screen aggressively for primary aldosteronism in resistant hypertension (prevalence 10-20%)
4. Utilize team-based care models and single-pill combinations to improve adherence
5. Maintain a low threshold for 24-hour ABPM to confirm diagnosis and exclude white-coat effect
6. Consider renal denervation in carefully selected patients with resistant hypertension after excluding secondary causes
7. Individualize blood pressure targets based on age, comorbidities, and patient preferences while following evidence-based guidelines

---

Selected References

1. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104.

2. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2018;71(6):e13-e115.

3. Freeman MW, Halvorsen YD, Marshall W, et al. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. N Engl J Med. 2023;388(5):395-405.

4. Schlaich MP, Bellet M, Weber MA, et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022;399(10333):1541-1551.

5. Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444-1451.

6. Azizi M, Sanghvi K, Saxena M, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021;397(10293):2476-2486.

7. Neal B, Wu Y, Feng X, et al. Effect of Salt Substitution on Cardiovascular Events and Death. N Engl J Med. 2021;385(12):1067-1077.

8. Zhang W, Zhang S, Deng Y, et al. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. N Engl J Med. 2021;385(14):1268-1279.

9. SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl Med. 2015;373(22):2103-2116.

10. Carey RM, Calhoun DA, Bakris GL, et al. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018;72(5):e53-e90.